Previous Close | 1.6400 |
Open | 1.6200 |
Bid | 1.6700 x 1000 |
Ask | 1.6700 x 1100 |
Day's Range | 1.5889 - 1.7000 |
52 Week Range | 1.0000 - 4.2500 |
Volume | |
Avg. Volume | 1,890,524 |
Market Cap | 5.094M |
Beta (5Y Monthly) | 1.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.4160 |
Earnings Date | Feb 09, 2023 - Feb 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for SNOA
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that it has entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of PrimocynTM Skin Solution products
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that Microcyn® Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA).
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care today announced that it has launched a line of office dispense products exclusively for skin care professionals.